Tislelizumab in combination with gemcitabine plus cisplatin chemotherapy as first-line adjuvant treatment for locally advanced or metastatic bladder cancer: a retrospective study

BACKGROUND: Combining immune checkpoint inhibitors with chemotherapy can synergistically improve antitumor activity and are generally well tolerated. Recently, the efficacy and safety of combination therapy has been demonstrated for many cancers, including urothelial carcinomas. The aim of this retr...

Descripción completa

Detalles Bibliográficos
Autores principales: Ren, Xiang, Tian, Yiqun, Wang, Zhixian, Wang, Jing, Li, Xing, Yin, Yisheng, Chen, Ruibao, Zhan, Ying, Zeng, Xiaoyong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9392937/
https://www.ncbi.nlm.nih.gov/pubmed/35987640
http://dx.doi.org/10.1186/s12894-022-01083-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9392937/
https://www.ncbi.nlm.nih.gov/pubmed/35987640
http://dx.doi.org/10.1186/s12894-022-01083-8

Ejemplares similares